Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06411899 · ClinicalTrials.gov registry record · Phase 3

A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

A Phase 3 study of Hidradenitis Suppurativa, sponsored by MoonLake Immunotherapeutics.

Active
Registry status
Phase 3
Development phase
422
Enrollment target
20
Study locations

NCT06411899 is a Phase 3 study of Hidradenitis Suppurativa that is active but no longer recruiting, run by MoonLake Immunotherapeutics. The registered enrollment target is 422 participants, below the 590-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (28% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06411899, a Phase 3 study of Hidradenitis Suppurativa, is active but no longer recruiting, sponsored by MoonLake Immunotherapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
422 participants
Enrollment target
20
Study locations

Study Summary

This is a study to evaluate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa. Participants will be randomized 2:1 to either sonelokimab or matching placebo up to Week 16.

Conditions Studied

Hidradenitis Suppurativa

Interventions

  • DRUG Placebo
  • DRUG Sonelokimab

Study Locations (20)

Florida

  • Clinical Site - Coral Gables
  • Clinical Site - Coral Springs
  • Clinical Site - Hollywood
  • Clinical Site - Margate
  • Clinical Site - Miami
  • Clinical Site - Tampa

California

  • Clinical Site - Los Angeles
  • Clinical Site - Northridge
  • Clinical Site - Sacramento
  • Clinical Site - San Diego

Georgia

  • Clinical Site - Macon
  • Clinical Site - Sandy Springs

Indiana

  • Clinical Site - Columbus
  • Clinical Site - New Albany

Massachusetts

  • Clinical Site - Boston
  • Clinical Site - Boston

Illinois

  • Clinical Site - West Dundee

Kentucky

  • Clinical Site - Louisville

Louisiana

  • Clinical Site - Metairie

Trial Details

FieldValue
Enrollment Target 422 participants
Start Date 2024-05-15
Est. Completion 2026-06-17
Phase Phase 3

Sponsor

MoonLake Immunotherapeutics

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06411899

The ClinicalTrials.gov registry entry for NCT06411899 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 422 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 590-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (28% lower). The listed sponsor is MoonLake Immunotherapeutics, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06411899 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT06411899 about?

NCT06411899 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa". This is a study to evaluate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa. Participants will be randomized 2:1 to either sonelokimab or matching placebo up to W...

What is the current status of trial NCT06411899?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 422 participants. The study started on 2024-05-15. Estimated completion is 2026-06-17.

What conditions does trial NCT06411899 study?

This clinical trial studies the following conditions: Hidradenitis Suppurativa.

What interventions are being tested in trial NCT06411899?

The interventions under investigation include: Placebo (DRUG), Sonelokimab (DRUG).

Who is sponsoring clinical trial NCT06411899?

This trial is sponsored by MoonLake Immunotherapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06411899 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hidradenitis Suppurativa

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hidradenitis Suppurativa

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.